Skip to main content

Table 2 Cycles received and off treatment reasons

From: A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

 

Cycles

  

Reasons off treatment

1

2

3

5

6

12

Total

(n)

(n)

(n)

(n)

(n)

(n)

(n)

(%)

Disease progression

1

1

1

1

2

1

7

50

Adverse events

3

     

3

21

Patient withdrawal

 

1

1

   

2

14

Alternative therapy

  

1

   

1

7

Other*

    

1

 

1

7

Total

4

2

3

1

3

1

14

100

  1. * 14009: MD decision to withdraw due to lack of efficacy and side effects.